NCT04950530View on ClinicalTrials.gov

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions

HIV-1-infection

Interventions

DRUG

BIKTARVY 50Mg-200Mg-25Mg Tablet

A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally

Trial Locations (1)

SW10 9NH

Chelsea & Westminster Hospital NHS Foundation Trust, London

All Listed Sponsors

lead

Chelsea and Westminster NHS Foundation Trust

OTHER